Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01984398 · ClinicalTrials.gov registry record · Phase 1
Comparison of Two Formulations of Androxal
A Phase 1 study, sponsored by Repros Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT01984398 is a Phase 1 study that has completed, run by Repros Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT01984398, a Phase 1 study, has completed, sponsored by Repros Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
To determine and compare the pharmacokinetics (PK) of a single dose of each of two formulations Androxal
Interventions
- DRUG 12.5 mg Androxal Formulation A
- DRUG 12.5 mg Androxal Formulation B
- DRUG 25 mg Androxal Formulation A
- DRUG 25 mg Androxal Formulation B
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-12-31 |
| Est. Completion | 2013-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01984398
The ClinicalTrials.gov registry entry for NCT01984398 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Repros Therapeutics, which has 50 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which 12.5 mg Androxal Formulation A is the first listed.
NCT01984398 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01984398 about?
NCT01984398 is a clinical study titled "Comparison of Two Formulations of Androxal". To determine and compare the pharmacokinetics (PK) of a single dose of each of two formulations Androxal
What is the current status of trial NCT01984398?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2013-12-31. Estimated completion is 2013-12-31.
What interventions are being tested in trial NCT01984398?
The interventions under investigation include: 12.5 mg Androxal Formulation A (DRUG), 12.5 mg Androxal Formulation B (DRUG), 25 mg Androxal Formulation A (DRUG), 25 mg Androxal Formulation B (DRUG).
Who is sponsoring clinical trial NCT01984398?
This trial is sponsored by Repros Therapeutics, which has 50 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.